Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical... see more

CSE:BIOV - Post Discussion

BioVaxys Technology Corp. > Sinovac
View:
Post by ChaseAckland on Jan 12, 2021 2:29pm

Sinovac

Today's WSJ is running an article on a Brazilian clinical study finding that the COVID-19 vaccine from Sinovac in China is almost 30 points less effective than origially claimed.  A very good reason for continued development efforts behind new SARS2 vaccines.   No way is this 'game over' with just two mRNA vaccines available. 

Here is the link
https://www.wsj.com/articles/chinas-sinovac-covid-19-vaccine-is-50-4-in-late-stage-brazil-trials-11610470581?mod=latest_headlines
Comment by frankman on Jan 13, 2021 10:01am
There are many other markets in Asia as well.BioVaxys is looking into. Today's WSJ is running an article on a Brazilian clinical study finding that the COVID-19 vaccine from Sinovac in China is almost 30 points less effective than origially claimed.  A very good reason for continued development efforts behind new SARS2 vaccines.   No way is this 'game over' with just ...more  
BioVaxys Technology Corp.